Press release
PI3K inhibitors Pipeline Insights, Clinical Trials, Emerging Therapies and Companies 2024
Discover the latest drugs and treatment options in the PI3K Inhibitors Pipeline. Dive into DelveInsight's comprehensive report today! @ PI3K Inhibitors Pipeline Outlook [https://www.delveinsight.com/sample-request/pi3k-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the PI3K inhibitors Pipeline Report
* In September 2024:- Scorpion Therapeutics Inc.- Study STX-478-101 is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 in participants with advanced solid tumors with P13Ka mutations.
* In September 2024:- Columbia University- Pilot Phase II Study of the PI3K Inhibitor Copanlisib in Combination With a Ketogenic Diet in the Treatment of Patients With Relapsed or Refractory Follicular Lymphoma or Endometrial Cancer. This is a multicenter, open label, pilot phase II study of the PI3K inhibitor copanlisib in combination with a ketogenic diet in the treatment of patients with one of the following malignancies: (a) relapsed or refractory (R/R) follicular lymphoma (FL), (b) R/R endometrial cancer (EC) with a documented activating mutation in PIK3CA or loss of phosphatase and tensin homolog (PTEN).
* DelveInsight's PI3K Inhibitors pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for PI3K Inhibitors treatment.
* The leading PI3K Inhibitors Companies such as TG Therapeutics, Pfizer, Incyte Corporation, Yuhan, Inflection Biosciences/AUM Biosciences, Onconova Therapeutics, UCB, and others.
* Promising PI3K Inhibitors Therapies such as Ribociclib, Fulvestrant, STX-478, Gedatolisib, Palbociclib, HMPL-689, and others.
Stay ahead with the most recent pipeline outlook for PI3K Inhibitors. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ PI3K Inhibitors Treatment Drugs [https://www.delveinsight.com/sample-request/pi3k-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
PI3K Inhibitors Emerging Drugs Profile
* Umbralisib: TG Therapeutics
Umbralisib (TGR-1202) is an oral, once daily, dual inhibitor of PI3K delta and CK1 epsilon. Umbralisib has nanomolar potency to the delta isoform of PI3K and high selectivity over the alpha, beta, and gamma PI3K isoforms. Umbralisib also uniquely inhibits casein kinase 1 epsilon (CK1 epsilon), which may have both direct anti-cancer effects and may also modulate T-cell activity associated with immune-mediated adverse events seen with previous PI3K inhibitors. Currently, umbralisib is being evaluated in Phase IIb and Phase III trials in patients with NHL and CLL.
* Gedatolisib: Pfizer
Gedatolisib (PF-05212384) is an experimental drug for treatment of cancer in development by Pfizer. It works by targeting PI3K/mTOR. The Phase II clinical trials of gedatolisib for treatment of endometrial cancer and colorectal cancer were terminated early due to enrollment issues. It is currently in phase II stage of development.
* Parsaclisib: Incyte Corporation
Parsaclisib is a potent, highly selective, next-generation PI3K inhibitor that is not associated with clinically meaningful transaminitis. It is in phase II stage of development.
* YH 25248: Yuhan
YH 25248 is an oral selective phosphatidylinositol 3-kinase (PI3K) delta inhibitor, being developed by Yuhan, for the treatment of cancer.
Explore groundbreaking therapies and clinical trials in the PI3K Inhibitors Pipeline. Access DelveInsight's detailed report now! @ New PI3K Inhibitors Drugs [https://www.delveinsight.com/sample-request/pi3k-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
PI3K inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
* Infusion
* Intradermal
* Intramuscular
* Intranasal
* Oral
* Parenteral
* Subcutaneous
* Topical.
* Molecule Type
PI3K Inhibitors Products have been categorized under various Molecule types such as
* Gene therapies
* Small molecule
* Vaccines
* Polymers
* Peptides
* Monoclonal antibodies
* Product Type
Unveil the future of PI3K Inhibitors Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ PI3K Inhibitors Market Drivers and Barriers [https://www.delveinsight.com/sample-request/pi3k-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the PI3K Inhibitors Pipeline Report
* Coverage- Global
* PI3K Inhibitors Companies- TG Therapeutics, Pfizer, Incyte Corporation, Yuhan, Inflection Biosciences/AUM Biosciences, Onconova Therapeutics, UCB, and others.
* PI3K Inhibitors Therapies- Ribociclib, Fulvestrant, STX-478, Gedatolisib, Palbociclib, HMPL-689, and others.
* PI3K Inhibitors Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* PI3K Inhibitors Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on PI3K Inhibitors Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ PI3K Inhibitors Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/pi3k-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* PI3K inhibitors: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* PI3K inhibitors - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* PI3K inhibitors Collaboration Deals
* Late Stage Products (Phase III)
* Umbralisib: TG Therapeutics
* Mid Stage Products (Phase II)
* Gedatolisib: Pfizer
* Parsaclisib: Incyte Corporation
* Early Stage Products (Phase I)
* Drug Name: Company Name
* Pre-clinical and Discovery Stage Products
* YH 25248: Yuhan
* Inactive Products
* PI3K inhibitors Key Companies
* PI3K inhibitors Key Products
* PI3K inhibitors- Unmet Needs
* PI3K inhibitors- Market Drivers and Barriers
* PI3K inhibitors- Future Perspectives and Conclusion
* PI3K inhibitors Analyst Views
* PI3K inhibitors Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=pi3k-inhibitors-pipeline-insights-clinical-trials-emerging-therapies-and-companies-2024]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release PI3K inhibitors Pipeline Insights, Clinical Trials, Emerging Therapies and Companies 2024 here
News-ID: 3681080 • Views: …
More Releases from ABNewswire
Nerve Growth Factor Market: Epidemiology, Therapies, Companies, DelveInsight | D …
DelveInsight's "Nerve growth factor (NGF) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Nerve growth factor, historical and forecasted epidemiology as well as the Nerve growth factor market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Nerve Growth Factor therapies are expected to boost the Nerve Growth Factor Market in the upcoming years.
DelveInsight has…
PI3K Inhibitor Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA App …
DelveInsight's, "PI3K Inhibitor Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in PI3K Inhibitor pipeline landscape. It covers the PI3K Inhibitor pipeline drug profiles, including PI3K Inhibitor clinical and nonclinical stage products. It also covers the PI3K Inhibitor therapeutics assessment by product type, stage, PI3K Inhibitor route of administration, and PI3K Inhibitor molecule type. It further highlights the inactive PI3K Inhibitor pipeline products in…
Sezary Syndrome Clinical Trials, Companies, Therapeutic Assessment, Therapies, T …
DelveInsight's, "Sezary Syndrome - Pipeline Insight, 2025," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Sezary Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
DelveInsight reports that over five key companies are actively developing…
HER2 Negative Metastatic Breast Cancer Clinical Trials, Companies, Therapeutic A …
DelveInsight's, "Her2 Negative Metastatic Breast Cancer- Pipeline Insight, 2025" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Her2 Negative Metastatic Breast Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
DelveInsight reports that over 50…
More Releases for PI3K
PI3K Inhibitors Market Projected to Witness Massive Growth - Novartis, Gilead Sc …
PI3K Inhibitors Market Snapshot
The PI3K Inhibitors Market is projected to reach USD 2.5 billion by 2032, growing at a CAGR of 8.2% from 2025 to 2032.
Coherent Market Insights proudly presents its latest PI3K Inhibitors Market Research Report, delivering a detailed examination of the U.S. PI3K Inhibitors Market outlook from 2025 to 2032. This comprehensive analysis provides strategic forecasts at both national and regional levels, addressing evolving supply networks, payer-provider collaboration,…
Global Jak And Pi3k Signaling Pathway Market Size by Application, Type, and Geog …
According to Market Research Intellect, the global Jak And Pi3k Signaling Pathway market under the Internet, Communication and Technology category is expected to register notable growth from 2025 to 2032. Key drivers such as advancing technologies, changing consumer behavior, and evolving market dynamics are poised to shape the trajectory of this market throughout the forecast period.
The JAK and PI3K signaling pathway market is experiencing significant growth due to the increasing…
JAK and PI3K Signaling Pathway Market Seeking Excellent Growth | Key Players: Ba …
Complete study of the global JAK and PI3K Signaling Pathway market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of the present as well as future scenario of the global JAK and PI3K Signaling Pathway industry. Research techniques like PESTLE and Porter's Five Forces analysis have been deployed…
Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Segmentation Analysis and Glo …
Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market: Overview
Metabolism of the human body relies on a variety of factors, and proper metabolism is essential to prevent several diseases. The development of tumours inside the body is largely due to improper cycles of metabolism. Medical researchers have demonstrated commendable accountability in dealing with chronic disorders and diseases. The cellular functions that run inside the body need be controlled and manoeuvred through proper drug…
Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Exclusive insight on Transfor …
Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market: Overview
Metabolism of the human body relies on a variety of factors, and proper metabolism is essential to prevent several diseases. The development of tumours inside the body is largely due to improper cycles of metabolism. Medical researchers have demonstrated commendable accountability in dealing with chronic disorders and diseases. The cellular functions that run inside the body need be controlled and manoeuvred through proper drug…
PI3K Signaling Pathway Market Growth with Worldwide Industry Analysis Up to 2025
A new research document with title 'PI3K Signaling Pathway Analysis: A Shifting Marketed and Pipeline Product Landscape, as Blockbusters Expire and Development Moves Towards Downstream Targets' covering detailed analysis, Competitive landscape, forecast and strategies. The study covers geographic analysis that includes regions like United States, Asia-Pacific, China, Japan, India, Asia and important players/vendors.The report will help user gain market insights, future trends and growth prospects for forecast period…
